rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Boundless Bio, Inc.

BOLD · Nasdaq

Health CareBiotechnologyLeading

BOLD stood above a rising 150-day average in 28 of the last 52 weekly readings, including each of the last 27 weeks. It is 10.7% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
27 in a row
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$3.4M
Insider sales, 12 months
$268K
Officials’ trades on record
0
Institutions holding
38 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 28 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$1.5MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months21
Sale orders, 12 months6
Buyers · sellers1 · 6
WhoDidSharesTraded
Kevin Tang10% ownerbought220at $2.3720 Oct 2026filed 20 Oct 2026
Kevin Tang10% ownerbought12,790at $2.3419 Oct 2026filed 20 Oct 2026
Kevin Tang10% ownerbought18,279at $2.3319 Oct 2026filed 20 Oct 2026
Kevin Tang10% ownerbought118,185at $2.3416 Oct 2026filed 20 Oct 2026
Kevin Tang10% ownersold18,300at $2.9726 Aug 2026filed 28 Aug 2026
Kevin Tang10% ownerbought2,975at $2.4421 Jul 2026filed 21 Jul 2026
Kevin Tang10% ownerbought1,623at $2.4420 Jul 2026filed 21 Jul 2026
Kevin Tang10% ownerbought265at $2.4417 Jul 2026filed 21 Jul 2026
Kevin Tang10% ownerbought18,491at $2.4416 Jul 2026filed 16 Jul 2026
Kevin Tang10% ownerbought1,600at $2.4415 Jul 2026filed 16 Jul 2026
Kevin Tang10% ownerbought43,878at $2.4314 Jul 2026filed 16 Jul 2026
Kevin Tang10% ownerbought48,211at $2.4213 Jul 2026filed 13 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders38+5 on the quarter
New · exited14 · 9
Reported value$37.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
ARCH Venture Management, LLCnew · filed 14 Aug 20262,694,095$6.7M+2,694,095
FMR LLCreduced · filed 13 Aug 20262,581,055$6.5M-114,400−4.2%
TANG CAPITAL MANAGEMENT LLCnew · filed 14 Aug 20262,559,875$6.4M+2,559,875
ADAR1 Capital Management, LLCnew · filed 14 Aug 20261,968,216$4.9M+1,968,216
Cormorant Asset Management, LPnew · filed 14 Aug 20261,000,000$2.5M+1,000,000
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026614,923$1.5M+17,731+3.0%
WELLINGTON MANAGEMENT GROUP LLPunchanged · filed 14 Aug 2026556,233$1.4M00.0%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 2026478,639$1.2M+378,764+379.2%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026471,570$1.2M+72,570+18.2%
Alyeska Investment Group, L.P.unchanged · filed 14 Aug 2026300,000$750K00.0%
31 Mar 2024 – 30 Jun 2026
344148Mar 24Sep 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Kevin Tang Company insider10% owner · last 20 Oct 202621 · 1
Tang Capital Management Llc Company insider10% owner · last 26 Aug 20260 · 1
ARCH Venture Fund IX, L.P. Company insider10% owner · last 1 Jul 20260 · 1
Arch Venture Partners Ix, L.p. Company insider10% owner · last 1 Jul 20260 · 1
Keith Crandell Company insider10% owner · last 1 Jul 20260 · 1
Steven Gillis Company insider10% owner · last 1 Jul 20261 · 1
James Christensen Company insiderDirector · last 15 Jun 20260 · 0
Jennifer Lew Company insiderDirector · last 15 Jun 20260 · 0
Jonathan E. Lim Company insiderDirector · last 15 Jun 20260 · 0
Nancy Whiting Company insiderDirector · last 15 Jun 20260 · 0
Christian Hassig Company insiderChief Scientific Officer · last 23 Jan 20260 · 0
David A. Hinkle Company insiderOfficer · last 23 Jan 20260 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-44.0%
Share count trendFY 2025 · to 2 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$17.9M
Free cash flowFY 2025 · to 31 Dec 2025−$47.2M

Analyst forecasts

No analyst forecasts yet.